BioLineRX rises after announcing collaboration for diabetes treatment


Higher by 6% in early action are shares of BioLineRX (BLRX).

The company has inked a development and commercialization agreement with JHL Biotech for the monoclonal antibody BL-9020 in Type 1 diabetes.

JHL will process and manufacture the treatment during pre-clinicals, while BLRX will shoulder pre-clinical development.

The companies will share responsibility for clinical development.

JHL will also have commercialization rights in China and SE Asia. (PR)

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs